Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma
George D. Glinos, William S. Fisher, Claudia Morr, Lucia Seminario‐Vidal
Abstract
Nivolumab is a fully humanized, monoclonal, IgG4 antibody targeting the programmed cell death protein 1 (PD-1) indicated for use as adjuvant therapy for advanced melanoma. Despite its efficacy in treating advanced melanoma it is associated with a variety of cutaneous toxicities, which are the most frequently reported adverse events.1,2 Psoriatic eruptions are well-described cutaneous reactions to PD-1 and programmed death-ligand 1 inhibitors.3-5 Standard therapies for these eruptions have consisted of topical and systemic agents, which are either only appropriate for short-term use, not entirely effective, or palliative.
Topics & Concepts
MedicineNivolumabPsoriasisMelanomaAdjuvantAdverse effectDermatologyAdjuvant therapyMonoclonal antibodyStage (stratigraphy)OncologyInternal medicineCancerImmunotherapyImmunologyCancer researchAntibodyBiologyPaleontologyPsoriasis: Treatment and PathogenesisCancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways